M⁶A regulator expression profile predicts the prognosis, benefit of adjuvant chemotherapy, and response to anti-PD-1 immunotherapy in patients with small-cell lung cancer.

ABSTRACT:

Background

Small cell lung cancer (SCLC) is lethal and possesses limited therapeutic options. Platinum-based chemotherapy-with or without immune checkpoint inhibitors (anti-PDs)-is the current first-line therapy for SCLCs; however, its associated outcomes are heterogeneous. N⁶-methyladenosine (m⁶A) is a novel and decisive factor in tumour progression, chemotherapy resistance, and immunotherapy response. However, m⁶A modification in SCLC remains poorly understood.

Methods

We systematically explored the molecular features and clinical significance of m⁶A regulators in SCLC. We then constructed an m⁶A regulator-based prognostic signature (m⁶A score) based on our examination of 256 cases with limited-stage SCLC (L

SUBMITTER: Zhang Z 

PROVIDER: S-EPMC8607595 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature